Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Bacteriophages Improve Outcome in Experimental Staphylococcus Aureus Ventilator Associated Pneumonia.

Prazak J, Iten M, Cameron DR, Save J, Grandgirard D, Resch G, Goepfert C, Leib SL, Takala J, Jakob SM, Que YA, Haenggi M.

Am J Respir Crit Care Med. 2019 Jul 1. doi: 10.1164/rccm.201812-2372OC. [Epub ahead of print]

PMID:
31260638
2.

Effects of 21st-century climate, land use, and disturbances on ecosystem carbon balance in California.

Sleeter BM, Marvin DC, Cameron DR, Selmants PC, Westerling AL, Kreitler J, Daniel CJ, Liu J, Wilson TS.

Glob Chang Biol. 2019 May 7. doi: 10.1111/gcb.14677. [Epub ahead of print]

PMID:
31066121
3.

Antibiotic resistance and host immune evasion in Staphylococcus aureus mediated by a metabolic adaptation.

Jiang JH, Bhuiyan MS, Shen HH, Cameron DR, Rupasinghe TWT, Wu CM, Le Brun AP, Kostoulias X, Domene C, Fulcher AJ, McConville MJ, Howden BP, Lieschke GJ, Peleg AY.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3722-3727. doi: 10.1073/pnas.1812066116. Epub 2019 Feb 11.

4.

Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves Mutations of the Essential Two-Component Regulator WalKR.

Jiang JH, Dexter C, Cameron DR, Monk IR, Baines SL, Abbott IJ, Spelman DW, Kostoulias X, Nethercott C, Howden BP, Peleg AY.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01926-18. doi: 10.1128/AAC.01926-18. Print 2019 Mar.

PMID:
30617095
5.

Carbapenemase-producing Enterobacteriaceae in Australian hospitals: outcome of point-prevalence screening in high-risk wards.

Brett JA, Johnson SA, Cameron DRM, Lane CR, Easton M, van Diemen A, Sutton B, Bull AL, Richards MJ, Worth LJ.

J Hosp Infect. 2019 Feb;101(2):163-166. doi: 10.1016/j.jhin.2018.08.008. Epub 2018 Aug 10.

PMID:
30102948
6.

A Genetic Determinant of Persister Cell Formation in Bacterial Pathogens.

Cameron DR, Shan Y, Zalis EA, Isabella V, Lewis K.

J Bacteriol. 2018 Aug 10;200(17). pii: e00303-18. doi: 10.1128/JB.00303-18. Print 2018 Sep 1.

7.

Making habitat connectivity a reality.

Keeley ATH, Basson G, Cameron DR, Heller NE, Huber PR, Schloss CA, Thorne JH, Merenlender AM.

Conserv Biol. 2018 Dec;32(6):1221-1232. doi: 10.1111/cobi.13158. Epub 2018 Sep 13.

PMID:
29920775
8.

Topical small molecule granzyme B inhibitor improves remodeling in a murine model of impaired burn wound healing.

Shen Y, Zeglinski MR, Turner CT, Raithatha SA, Wu Z, Russo V, Oram C, Hiroyasu S, Nabai L, Zhao H, Bozin T, Westendorf K, Kopko I, Huang R, Arns S, Tan J, Zeng H, Boey A, Liggins R, Jaquith J, Cameron DR, Papp A, Granville DJ.

Exp Mol Med. 2018 May 30;50(5):68. doi: 10.1038/s12276-018-0095-0.

9.

Ecosystem management and land conservation can substantially contribute to California's climate mitigation goals.

Cameron DR, Marvin DC, Remucal JM, Passero MC.

Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):12833-12838. doi: 10.1073/pnas.1707811114. Epub 2017 Nov 13.

10.

Mediterranean California's water use future under multiple scenarios of developed and agricultural land use change.

Wilson TS, Sleeter BM, Cameron DR.

PLoS One. 2017 Oct 31;12(10):e0187181. doi: 10.1371/journal.pone.0187181. eCollection 2017.

11.

Vancomycin-intermediate Staphylococcus aureus isolates are attenuated for virulence when compared with susceptible progenitors.

Cameron DR, Lin YH, Trouillet-Assant S, Tafani V, Kostoulias X, Mouhtouris E, Skinner N, Visvanathan K, Baines SL, Howden B, Monk IR, Laurent F, Stinear TP, Howden BP, Peleg AY.

Clin Microbiol Infect. 2017 Oct;23(10):767-773. doi: 10.1016/j.cmi.2017.03.027. Epub 2017 Apr 7.

12.
13.

Antibiotic regimen based on population analysis of residing persister cells eradicates Staphylococcus epidermidis biofilms.

Yang S, Hay ID, Cameron DR, Speir M, Cui B, Su F, Peleg AY, Lithgow T, Deighton MA, Qu Y.

Sci Rep. 2015 Dec 21;5:18578. doi: 10.1038/srep18578.

14.

Insights on virulence from the complete genome of Staphylococcus capitis.

Cameron DR, Jiang JH, Hassan KA, Elbourne LD, Tuck KL, Paulsen IT, Peleg AY.

Front Microbiol. 2015 Sep 23;6:980. doi: 10.3389/fmicb.2015.00980. eCollection 2015.

15.

Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene.

Bæk KT, Thøgersen L, Mogenssen RG, Mellergaard M, Thomsen LE, Petersen A, Skov S, Cameron DR, Peleg AY, Frees D.

Antimicrob Agents Chemother. 2015 Nov;59(11):6983-91. doi: 10.1128/AAC.01303-15. Epub 2015 Aug 31.

16.

Identification of a Class of Protein ADP-Ribosylating Sirtuins in Microbial Pathogens.

Rack JG, Morra R, Barkauskaite E, Kraehenbuehl R, Ariza A, Qu Y, Ortmayer M, Leidecker O, Cameron DR, Matic I, Peleg AY, Leys D, Traven A, Ahel I.

Mol Cell. 2015 Jul 16;59(2):309-20. doi: 10.1016/j.molcel.2015.06.013. Epub 2015 Jul 9.

17.

Draft Genome Sequences of Clinical Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strain APS211 and Its Daptomycin-Susceptible Progenitor APS210.

Cameron DR, Jiang JH, Abbott IJ, Spelman DW, Peleg AY.

Genome Announc. 2015 Jun 11;3(3). pii: e00568-15. doi: 10.1128/genomeA.00568-15.

18.

Impact of daptomycin resistance on Staphylococcus aureus virulence.

Cameron DR, Mortin LI, Rubio A, Mylonakis E, Moellering RC Jr, Eliopoulos GM, Peleg AY.

Virulence. 2015;6(2):127-31. doi: 10.1080/21505594.2015.1011532.

19.

Whither the Rangeland?: Protection and conversion in California's Rangeland ecosystems.

Cameron DR, Marty J, Holland RF.

PLoS One. 2014 Aug 20;9(8):e103468. doi: 10.1371/journal.pone.0103468. eCollection 2014.

20.

Applications of comparative effectiveness research to case management.

Moreo K, Greene L, Sapir T, Cameron DR.

Prof Case Manag. 2013 Jul-Aug;18(4):168-79; quiz 180-1. doi: 10.1097/NCM.0b013e3182901e57.

PMID:
23735965
21.

Peripheral intravenous catheter-associated Staphylococcus aureus bacteraemia: more than 5 years of prospective data from two tertiary health services.

Stuart RL, Cameron DR, Scott C, Kotsanas D, Grayson ML, Korman TM, Gillespie EE, Johnson PD.

Med J Aust. 2013 Jun 3;198(10):551-3.

PMID:
23725270
22.

The RpoB H₄₈₁Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus.

Gao W, Cameron DR, Davies JK, Kostoulias X, Stepnell J, Tuck KL, Yeaman MR, Peleg AY, Stinear TP, Howden BP.

J Infect Dis. 2013 Mar 15;207(6):929-39. doi: 10.1093/infdis/jis772. Epub 2012 Dec 18.

23.

Incorporating the treat-to-target concept in rheumatoid arthritis.

Ruderman EM, Nola KM, Ferrell S, Sapir T, Cameron DR.

J Manag Care Pharm. 2012 Nov-Dec;18(9):1-18.

24.

Significant reduction in vancomycin-resistant enterococcus colonization and bacteraemia after introduction of a bleach-based cleaning-disinfection programme.

Grabsch EA, Mahony AA, Cameron DR, Martin RD, Heland M, Davey P, Petty M, Xie S, Grayson ML.

J Hosp Infect. 2012 Dec;82(4):234-42. doi: 10.1016/j.jhin.2012.08.010. Epub 2012 Oct 25.

PMID:
23103245
25.

An approach to enhance the conservation-compatibility of solar energy development.

Cameron DR, Cohen BS, Morrison SA.

PLoS One. 2012;7(6):e38437. doi: 10.1371/journal.pone.0038437. Epub 2012 Jun 7.

26.

Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.

Singh JA, Cameron DR.

J Manag Care Pharm. 2012 May;18(4 Supp C):S1-18. Review.

PMID:
22656072
27.

Economic costs of achieving current conservation goals in the future as climate changes.

Shaw MR, Klausmeyer K, Cameron DR, Mackenzie J, Roehrdanz P.

Conserv Biol. 2012 Jun;26(3):385-96. doi: 10.1111/j.1523-1739.2012.01824.x. Epub 2012 Apr 12.

PMID:
22497365
28.

Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus.

Cameron DR, Ward DV, Kostoulias X, Howden BP, Moellering RC Jr, Eliopoulos GM, Peleg AY.

J Infect Dis. 2012 Jun;205(11):1677-87. doi: 10.1093/infdis/jis252. Epub 2012 Apr 5.

29.

Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus.

Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC Jr, Eliopoulos GM.

PLoS One. 2012;7(1):e28316. doi: 10.1371/journal.pone.0028316. Epub 2012 Jan 6.

30.

The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes.

Cameron DR, Howden BP, Peleg AY.

Clin Infect Dis. 2011 Sep;53(6):576-82. doi: 10.1093/cid/cir473. Review.

PMID:
21865195
31.

Novel antimicrobial lipopeptides with long in vivo half-lives.

Pasetka CJ, Erfle DJ, Cameron DR, Clement JJ, Rubinchik E.

Int J Antimicrob Agents. 2010 Feb;35(2):182-5. doi: 10.1016/j.ijantimicag.2009.10.013. Epub 2009 Dec 16.

PMID:
20006467
32.

Staphylococcus aureus bacteraemia as a quality indicator for hospital infection control.

Dendle C, Martin RD, Cameron DR, Grabsch EA, Mayall BC, Grayson ML, Johnson PD.

Med J Aust. 2009 Oct 5;191(7):389-92.

PMID:
19807631
33.

Semisynthetic approaches to laspartomycin analogues.

Curran WV, Leese RA, Jarolmen H, Borders DB, Dugourd D, Chen Y, Cameron DR.

J Nat Prod. 2007 Mar;70(3):447-50. Epub 2007 Feb 27.

PMID:
17323996
34.

Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach.

Goudreau N, Cameron DR, Déziel R, Haché B, Jakalian A, Malenfant E, Naud J, Ogilvie WW, O'meara J, White PW, Yoakim C.

Bioorg Med Chem. 2007 Apr 1;15(7):2690-700. Epub 2007 Jan 24.

PMID:
17306550
35.

Conservation planning for ecosystem services.

Chan KM, Shaw MR, Cameron DR, Underwood EC, Daily GC.

PLoS Biol. 2006 Oct;4(11):e379.

36.

The use of dehydroepiandrosterone therapy in clinical practice.

Cameron DR, Braunstein GD.

Treat Endocrinol. 2005;4(2):95-114. Review.

PMID:
15783247
37.

Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics.

Goudreau N, Brochu C, Cameron DR, Duceppe JS, Faucher AM, Ferland JM, Grand-Maître C, Poirier M, Simoneau B, Tsantrizos YS.

J Org Chem. 2004 Sep 17;69(19):6185-201.

PMID:
15357576
38.

Delayed cholecystectomy for gallstone pancreatitis: re-admissions and outcomes.

Cameron DR, Goodman AJ.

Ann R Coll Surg Engl. 2004 Sep;86(5):358-62.

39.

Androgen replacement therapy in women.

Cameron DR, Braunstein GD.

Fertil Steril. 2004 Aug;82(2):273-89. Review.

PMID:
15302268
40.

Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position.

Rancourt J, Cameron DR, Gorys V, Lamarre D, Poirier M, Thibeault D, Llinàs-Brunet M.

J Med Chem. 2004 May 6;47(10):2511-22.

PMID:
15115394
41.

NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.

Goudreau N, Cameron DR, Bonneau P, Gorys V, Plouffe C, Poirier M, Lamarre D, Llinas-Brunet M.

J Med Chem. 2004 Jan 1;47(1):123-32.

PMID:
14695826
42.

Xylose fermentation by genetically modified Saccharomyces cerevisiae 259ST in spent sulfite liquor.

Helle SS, Murray A, Lam J, Cameron DR, Duff SJ.

Bioresour Technol. 2004 Apr;92(2):163-71.

PMID:
14693449
43.

Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor.

Wang Y, Coulombe R, Cameron DR, Thauvette L, Massariol MJ, Amon LM, Fink D, Titolo S, Welchner E, Yoakim C, Archambault J, White PW.

J Biol Chem. 2004 Feb 20;279(8):6976-85. Epub 2003 Nov 22.

44.

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.

Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagacé L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinàs-Brunet M.

Nature. 2003 Nov 13;426(6963):186-9. Epub 2003 Oct 26. Erratum in: Nature. 2003 Nov 20;246.

45.

Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.

Tsantrizos YS, Bolger G, Bonneau P, Cameron DR, Goudreau N, Kukolj G, LaPlante SR, Llinàs-Brunet M, Nar H, Lamarre D.

Angew Chem Int Ed Engl. 2003 Mar 28;42(12):1356-60. No abstract available.

PMID:
12671967
46.

Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain.

Proudfoot JR, Betageri R, Cardozo M, Gilmore TA, Glynn S, Hickey ER, Jakes S, Kabcenell A, Kirrane TM, Tibolla AK, Lukas S, Patel UR, Sharma R, Yazdanian M, Moss N, Beaulieu PL, Cameron DR, Ferland JM, Gauthier J, Gillard J, Gorys V, Poirier M, Rancourt J, Wernic D, Llinas-Brunet M.

J Med Chem. 2001 Jul 19;44(15):2421-31.

PMID:
11448224
47.

Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease.

Poupart MA, Cameron DR, Chabot C, Ghiro E, Goudreau N, Goulet S, Poirier M, Tsantrizos YS.

J Org Chem. 2001 Jul 13;66(14):4743-51.

PMID:
11442398
48.

NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain.

LaPlante SR, Aubry N, Bonneau PR, Kukolj G, Lamarre D, Lefebvre S, Li H, Llinàs-Brunet M, Plouffe C, Cameron DR.

Bioorg Med Chem Lett. 2000 Oct 16;10(20):2271-4.

PMID:
11055336
49.

2',6'-Dimethylphenoxyacetyl: a new achiral high affinity P(3)-P(2) ligand for peptidomimetic-based HIV protease inhibitors.

Beaulieu PL, Anderson PC, Cameron DR, Croteau G, Gorys V, Grand-Maître C, Lamarre D, Liard F, Paris W, Plamondon L, Soucy F, Thibeault D, Wernic D, Yoakim C, Pav S, Tong L.

J Med Chem. 2000 Mar 23;43(6):1094-108.

PMID:
10737742
50.

Solution structure of substrate-based ligands when bound to hepatitis C virus NS3 protease domain.

LaPlante SR, Cameron DR, Aubry N, Lefebvre S, Kukolj G, Maurice R, Thibeault D, Lamarre D, Llinàs-Brunet M.

J Biol Chem. 1999 Jun 25;274(26):18618-24.

Supplemental Content

Loading ...
Support Center